CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Agalsidase beta

Agalsidase beta

Last Updated: December 10, 2004

Result type: Reports

Project Number: SR0028-000

Product Line: Reimbursement Review

Generic Name: Agalsidase beta

Brand Name: Fabrazyme

Manufacturer: Genzyme Canada

Therapeutic Area: Fabry Disease

Indications: Fabry Disease

Submission Type: Resubmission

Project Status: Complete

Date Recommendation Issued: May 18, 2005

Recommendation Type: Do not list

Agalsidase beta

Files